Rational design and development of colon-specific prodrugs

Current Topics in Medicinal Chemistry

Volumn 11, Issue 18, 2011, Pages 2318-2345

  Dhaneshwar, Suneela S ^a   Vadnerkar, Gaurav ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Amoebiasis; Colon cancer; Colon specific prodrugs; Inflammatory bowel disease; Irritable bowel syndrome

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; BEVACIZUMAB; BUDESONIDE; CETUXIMAB; CORTICOSTEROID; CYCLOSPORIN A; FLUOROURACIL; INTERLEUKIN 6; INTERLEUKIN 8; INTESTINOL; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYAMIDOAMINE; PREDNISOLONE; PRODRUG; RIFAXIMIN; S ADENOSYLMETHIONINE; SALAZOSULFAPYRIDINE; TAURINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; AGRANULOCYTOSIS; AMEBIASIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; BIRTH DEFECT; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CATARACT; CELL DIFFERENTIATION; COLON FLORA; COLORECTAL CANCER; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONVULSION; CROHN DISEASE; CYTOKINE PRODUCTION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERANCE; ENTERITIS; FATIGUE; FETUS DEATH; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; GLAUCOMA; GLOSSITIS; HEMOLYTIC ANEMIA; HEPATITIS; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYDROPHILICITY; HYPERTENSION; ILEITIS; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; INSOMNIA; INTESTINE TRANSIT TIME; IRRITABILITY; IRRITABLE COLON; KIDNEY FAILURE; KIDNEY INJURY; LEUKEMIA; LEUKOPENIA; LIPID PEROXIDATION; LIVER DISEASE; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; MALE INFERTILITY; MENSTRUAL IRREGULARITY; MUSCLE ATROPHY; NAUSEA; NEPHRITIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; OXIDATIVE STRESS; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PERSONALITY DISORDER; PNEUMONIA; PSYCHOSIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SHELF LIFE; SIDE EFFECT; SPONTANEOUS ABORTION; STOMACH MOTILITY; STOMACH PH; STOMACH PRESSURE; STOMACH SECRETION; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; ULCERATIVE COLITIS; URTICARIA; VOMITING; WEIGHT GAIN;

ANIMALS; COLONIC DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; ORGAN SPECIFICITY; PRODRUGS;

EID: 80052229826     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611797183249     Document Type: Review

References (276)

1. Mrsny, R. J. The colon as a site for drug delivery. J. Control. Release, 1992, 22, 15-34.
2. Sousa, T.; Paterson, R.; Mooreb, V.; Carlssonurl, A.; Abrahamsson, B.; Basit, A. W. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 2008, 363, 1-25.
3. Friend, D. R. Colon-specific drug delivery. Adv. Drug Deliv. Rev., 1991, 7, 149-199.
4. Bieck, P. R. In: Drug Absorption from the Human Colon. Drug Delivery to Gastrointestinal Tract. Hardy, J. G.; Davis, S. S.; Wilson, C. G.; Eds.; Ellis Horwood: Chichester, UK, 1989; pp 25-30.
5. Krishnaiah, Y. S. R.; Satyanarayana, S. Colon-specific Drug Delivery Systems. In Advances in Controlled and Novel Drug Delivery. Jain, N. K.; Ed.; CBS Publisher: New Delhi, 2001; pp 89-119.
6. Keshav, S. The Gastrointestinal System at a Glance. Blackwell Science: Oxford, 2004; pp 12-38.
7. Dressman, J.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption; immediate release dosage forms. Pharm. Res., 1998, 15, 11-22.
8. Hardy, J. G. In: Colonic Transit and Drug Delivery. Drug Delivery to Gastrointestinal Tract. Hardy, J. G.; Davis, S. S.; Wilson C. G.; Eds.; Ellis Horwood: Chichester, UK, 1989, pp 75-81.
9. Khosla, R.; Davis, S. S. Gastric emptying and small and larger bowel transit of non-disintegrating tablets in fasted subjects. Int. J. Pharm., 1989, 52, 1-10.
10. Enck, P.; Merlin, V.; Erckenbrecht, J. F.; Wienbeck, M. Stress effects on gastrointestinal transit in the rat. Gut, 1989, 30, 455-459.
11. Scheline, R. R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev., 1973, 25, 451-523.
12. Abu Shamat, M. The role of the gastrointestinal microflora in the metabolism of drugs. Int. J. Pharm., 1993, 97, 1-13.
13. Mikov, M. The Metabolism of drugs by the gut flora. Eur. J. Drug Metab. Pharmacokinet., 1994, 19, 201-207.
14. Haeberlin, B. In: Anatomy and Physiology of the Gastrointestinal Tract: Implication for Colonic Drug Delivery. Oral Colon-Specific Drug Delivery. Friend D. R.; Ed.; CRC Press: Boca Raton, FL, 1992; pp 1-43.
15. Faigle, J. W. In: Drug Metabolism in the Colon Wall and Lumen. Colonic Drug Absorption and Metabolism. Bieck, P. R.; Ed.; Marcel Dekker, Inc: NY, 1993; pp. 29-54.
16. Yang, L.; Chu, J. S.; Fix, J. A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm., 2002, 235, 1-15.
17. Rowland, I. R.; Mallett, A. K.; Bearne, C. A.; Farthing, M. J. G. Enzyme activities of the hindgut microflora of laboratory animals and man. Xenobiotica, 1986, 16, 519-523.
18. http://www.textbookofbacteriology.net pg 1-3 accessed on 03/01/10.
19. Longer, M. A.; Woodley, J. F.; Duncan, R. Comparison of the activities of rat small intestine and colon brush border membrane peptidases, Proc. Int. Symp. Controlled Release Bioact. Mater, 1989, 16, 225-226.
20. MacFarlane, G. T.; Cummings, J. H.; MacFarlane S.; Gibson, G. R. Influence of retention time on degradation of pancreatic enzymes by colonic bacteria grown in a 3-stage continuous culture system, J. Appl. Bacteriol., 1989, 67, 521-527.
21. Kopecek, J.; Kopecek, P.; Bronsted, H.; Rathi, R.; Rihova, B.; Yeh, P. Y.; Ikesue, K. Polymers for colon specific drug delivery, Fifth Intl. Symp. Recent Adv. Drug Deliv. Syst. Abstracts, 1991, 27-28.
22. Davis, S. S. Overcoming barriers to the oral administration of pep-tide drugs. Trends Pharm. Sci., 1990, 11, 353-355.
23. Digenis, G. A.; Sandefer, E. Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit. Rev. Ther. Drug Carrier Syst., 1991, 7, 309-345.
24. Taniguchi, K.; Muranishi, S.; Sezaki, H. Enhanced intestinal permeability to macramolecules II. improvement of the large intestinal absorption of heparin by lipid-surfactant mixed micelles in rat. Int. J. Pharm., 1980, 4, 219-228.
25. Bussemer, T.; Otto, I.; Bodmeier, R. Pulsatile drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18, 433-458.
26. Kinget, R.; Kalala, W.; Vervoort, L.; Van den Mooter, G. Colonic drug targeting. J. Drug Target, 1998, 6, 129-149.
27. Friend, D. R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev., 2005, 57, 247-265.
28. Chourasia, M. K.; Jain, S. K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci., 2003, 6, 33-66.
29. Chae, S. Y.; Jang, M. K.; Nah, J. W. Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Release, 2005, 102, 383-394.
30. Ungell, A. L.; Nylander, S.; Bergstrand, S.; Sjoberg A.; Lennernas, H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci., 1998, 87, 360-366.
31. Sinha, V. R.; Kumria, R. Colonic drug delivery: prodrug approach. Pharm. Res., 2001, 18, 557-564.
32. Doh, M. J.; Jung, Y. J.; Kim, I.; Kong, H. S.; Kim, Y. M. Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone. Arch. Pharm. Res., 2003, 26, 258-263.
33. Jung, Y. J.; Lee, J. S.; Kim, Y. M. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci., 2000, 89(5), 594-602.
34. Friend, D. R.; Chang, G. W. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. Chem., 1984, 27, 261-266.
35. Minami, K.; Hirayama, F.; Uekama, K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenyly-lacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J. Pharm. Sci., 1998, 87, 715-720.
36. Harboe, E.; Larsen, C., Johansen, M.; Olesen, H. P. Macromolecu-lar prodrugs. XV. colon targeted delivery-bioavailability of naproxen from orally administered dextran naproxen ester prodrugs varying in molecular size in the pig. Pharm. Res., 1989, 6, 919-923.
37. Leopold, C. S.; Friend, D. R. In vivo pharmacokinetic study for the assessment of poly-(l-aspartic acid) as a drug carrier for colon-specific drug delivery. J. Pharmacokinet. Biopharm., 1995, 23, 397-406.
38. Raghavan, C. V.; Muthulingam, C.; Jenita, J. A.; Ravi, T. K. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem. Pharm. Bull., 2002, 50, 892-895.
39. Rubinstein, A.; Nakar, D.; Sintov, A. Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm. Res., 1992, 9, 276-278.
40. Krishnaiah, Y. S.; Satyanarayana, V.; Dinesh Kumar, B.; Karthike-yan, R. S.; Bhaskar, P. In vivo evaluation of guar gum based colon targeted oral drug delivery systems of celecoxib in human volunteers. Eur. J. Drug Metab. Pharmacokinet., 2002, 27, 273-280.
41. Krishnaiah, Y. S.; Satyanarayana, V.; Dinesh Kumar, B.; Karthike-yan, R. S. In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur. J. Pharm. Sci., 2002, 16, 185-192.
42. Sinha, V. R.; Kumria, R. Polysaccharides in Colon-specific drug delivery. Int. J. Pharm., 2001, 224, 19-38.
43. El-Gibaly, I. Oral Delayed-release system based on zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int. J. Pharm., 2002, 232, 199-211.
44. Van den Mooter, G.; Vervoort, L.; Kinget, R. Characterization of methacrylated inulin hydrogels designed for colon targeting: in vitro release of BSA. Pharm. Res., 2003, 20, 303-307.
45. Wiwattanapatapee, R.; Lomlim, L.; Saramunee, K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J. Control. Release, 2003, 88, 1-9.
46. Brown, J. P.; McGarraugh, G. V.; Parkinson, T. M.; Wingard, R. E.; Onderdonk, A. B. A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem., 1983, 26, 1300-1307.
47. Sakuma, S.; Lu, Z. R.; Kopeckova, P.; Kopecek J. Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J. Control. Release, 2001, 75(3), 365-379.
48. http://www.ccfa.org/physician/colitisb.html pp 1-5 [accessed on 20/08/2008].
49. http://www.niddk.nih.gov/health/digest/pubs/colitis/colitis.htm pp 1-5 [accessed on 20/08/2008].
50. Van Bodegraven, A. A.; Wijmenga, C. In: Inflammatory Bowel Disease. Genomic and Personalized Medicine. Willard, H. F.; Ginsburg, G. S.; Eds.; Elsevier Inc.: Philadelphia, 2009; pp. 1040-1055.
51. Sartor, R. B. Enteric microflora in IBD: pathogens or commensals? Inflamm. Bowel Dis., 1997, 3, 230-235.
52. Robertson, D. J.; Sandler, R. S. Measles virus and crohn's disease: a critical appraisal of the current literature. Inflamm. Bowel Dis., 2001, 7, 51-57.
53. Sartor, R. B. In: Microbial Factors in the Pathogenesis of Crohn's Disease, Ulcerative Colitis and Experimental Intestinal Inflammation. Inflammatory Bowel Disease; Kirsner, J. B.; Shorter, R. G.; Eds.; Williams and Wilkens: Baltimore, 1995; pp. 96-124.
54. Sands, B. E. Inflammatory bowel disease: past, present and future. J. Gastroenterol., 2007, 42, 16-25.
55. http://my.clevelandclinic.org/disorders/inflammatory_bowel_disease/dd_overview.aspx. Pp. 1-3 [accessed on 08/03/10].
56. Meyers, S.; Sachar, D. B. In: Medical Therapy of Crohn's Disease. Inflammatory Bowel Disease. Kersnar, J. B.; Shorter, R. G.; Eds.; Williams and Wilkins: Baltimore, 1995, pp. 695-714.
57. Rhodes, J.; Thomas, G.; Evans, B. K. Inflammatory bowel disease management: some thoughts on future drug development. Drugs, 1997, 53, 189-194.
58. Head, K. A.; Jurenka, J. S. Inflammatory bowel disease part I: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Alt. Med. Rev., 2003, 8(3), 247-283.
59. Hartley, M. G.; Hudson, M. J.; Swarbrick, E. T.; Hill, M. J.; Gent, A. E.; Hellier, M. D.; Grace, R. H. The rectal mucosa-associated microflora in patients with ulcerative colitis. J. Med. Microbiol, 1992, 36, 96-103.
60. Silva, M.; Jacobus, N. V.; Deneke, C; Gorbach, S. L. Antimicrobial substance from a human lactobacillus strain. Antimicrob. Agents Chemother., 1987, 31, 1231-1233.
61. Svartz, N. Salazopyrin-a new sulfanilamide preparation. A. therapeutic result in rheumatoid arthritis. B. Therapeutic results in ulcerative colitis. C. toxic manifestations on treatment with sulpha-nilamide preparations. Acta. Med. Scand, 1942, 110, 577-590.
62. Adamson, D. J.; Frew, D.; Tatoud, R.; Wolf, C. R.; Palmer, C. N. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol. Pharmacol, 2002, 61, 7-12.
63. Hawkey C. J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology, 2000, 119, 521-535.
64. Dubuquoy, L.; Rousseaux, C; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPARy as a new therapeutic target in inflammatory bowel disease. Gut, 2006, 55, 1341-1349.
65. Bus, P. J.; Nagtegaal, I. D.; Verspaget, H. W.; Lamers, C. B.; Geldof, H.; Van Krieken, J. H.; Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreven-tive era? Aliment. Pharmacol. Ther., 1999, 13, 1397-1402.
66. Pearson, D. C; Jourd'Heuil D.; Meddings J. B. The anti-oxidant properties of 5-aminosalicylic acid. Free Radic. Biol. Med., 1996, 21(3), 367-373.
67. Arend, L. J.; Springate, J. E. Interstitial Nephritis from Mesalazine: Case Report and Literature Review. Pediatr. Nephrol. 2004, 19, 550-553.
68. Mahmud, N.; O'Toole, D.; O'Hare, N.; Freyne, P. J.; Weir, D. G.; Kelleher, D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment. Pharmacol. Ther., 2002, 16, 207-215.
69. Deprez, P.; Descamps, C; Fiasse, R. Pancreatitis induced by 5-aminosalicylic acid. Lancet 1989, 2, 445-446.
70. Paoluzi, P.; D'Albasio, G.; Pera, A.; Bianchi Porro, G.; Paoluzi, O. A.; Pica, R.; Cottone, M.; Miglioli, M.; Prantera, C; Sturniolo, G.; Ardizzone, S. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one year randomised multicentre trial. Dig. Liver Dis., 2002, 34, 787-793.
71. Hein, D.W.; Doll, M. A.; Fretland, A. J.; Leff, M. A.; Webb, S. J.; Xiao, G. H. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 29-42.
72. Klotz, U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig. Liver Dis., 2005, 37, 381-388.
73. Volin, M. V.; Campbell, P. L.; Connors, M. A.; Woodruff, D. C; Koch, A. E. The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp. Mol. Pathol, 2002, 73, 84-92.
74. Pullar, T.; Hunter, J. A.; Capell, H. A. Which component of sul-phasalazine is active in rheumatoid arthritis? Br. Med. J. Clin. Res., 1985, 290, 1535-1538.
75. Taggart, A. J.; Neumann, V. C; Hill, J.; Astbury, C; Gallez, L. P.; Dixon, J. S. Which is the active moiety of sulphasalazine in rheumatoid arthritis 5-ASA or sulphapyridine? Drugs, 1986, 31, 27-34.
76. Neumann, V. C; Taggart, A. J.; Gallez, L. P.; Astbury, C; Hill, J.; Bird, H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J. Rheumatol, 1986, 13, 285-297.
77. Bird, H. A. Sulphasalazine, Sulphapyridine or 5-aminosalicylic acid - which is the active moiety in rheumatoid arthritis? Br. J. Rheumatol, 1995, 34(2), 16-19.
78. Peppercorn, M. A.; Goldman, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther., 1972, 181, 555-562.
79. Jani, N.; Regueiro, M. D. Medical therapy for ulcerative colitis. Gastroenterol. Clin. N. Am., 2002, 31, 147-166.
80. Das, K. M.; Eastwood, M. A.; McManus, J. P. A.; Sircus, W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N. Engl. J. Med., 1973, 289, 491-495.
81. Fischer, C.; Klotz, U. Is plasma level monitoring of sulfasalazine indicated in the treatment of crohn's disease or ulcerative colitis? Ther. Drug Monit., 1980, 2, 153-158.
82. Farrell, R.; Peppercorn, M. A. Ulcerative colitis. Lancet, 2002, 359, 331-40.
83. Prakash, A.; Spencer, C. M. Balsalazide. Drugs, 1998, 56, 83-90.
84. Muijsers, R. B. R.; Goa, K. L. Balsalazide. A review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs, 2002, 62, 1689-1705.
85. Ryde, E. M.; Ahnfelt, N. O. The pharmacokinetics of olsalazine sodium in healthy volunteers after a single I.V. dose and after oral doses with and without food. Eur. J. Clin. Pharmacol., 1988, 34, 481-488.
86. Sandberg-Gertzen, H.; Ryde, M.; Jarnerot, G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand. J. Gastroenterol., 1983, 18, 107-111.
87. Klotz, U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur. J. Clin. Pharmacol., 2000, 56, 353-362.
88. Wadworth, A. N.; Fitton, A. Olsalazine. A review of its pharma-codynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs, 1991, 41, 647-664.
89. Robinson, M. G. New Oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Gastroenterol. Clin. N. Am. 1989, 18, 43-50.
90. Chan, R. P.; Pope, D. J.; Gilbert, A. P.; Sacra, P. J.; Baron, J. H.; Lennard-Jones, J. E. Studies of two novel sulfasalazine analogs, ip-salazide and balsalazide. Dig. Dis. Sci., 1983, 28, 609-615.
91. Baron, J. H.; Connell, A. M.; Lennard-Jones, J. E.; Avery Jones, F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet, 1962, 2, 1094-1096.
92. Yamaguchi, T.; Sasaki, K.; Kurosaki, Y.; Nakayama, T.; Kimura, T. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic Acid. J. Drug Target, 1994, 2(2), 123-131
93. Peppercorn, M. A.; Goldman, P. Drug-bacteria interactions. Rev. Drug Inter., 1976, 2, 75-88.
94. Nagpal, D.; Singh, R.; Gairola, N.; Bodhankar, S. L.; Dhaneshwar, S. S. Mutual azo prodrug of 5-aminosalicylic acid for colon targeted drug delivery: synthesis, kinetic studies and pharmacological evaluation. Ind. J. Pharm. Sci., 2006, 68(2), 171-178.
95. Dhaneshwar, S. S.; Gairola, N.; Kandpal, M.; Vadnerkar, G.; Bhatt, L.; Rathi, B.; Kadam, S. S. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon specific drug delivery in inflammatory bowel disease. Eur. J. Med. Chem., 2009, 44, 3922-3929.
96. Dhaneshwar, S. S.; Kandpal, M.; Vadnerkar, G. L-glutamine conjugate of meselamine: a novel approach for targeted delivery to colon. J. Drug Del. Sci. Tech., 2009, 19(1), 67-72.
97. Cassano, R.; Trombino, S.; Cilea, A.; Ferrarelli, T.; Muzzalupo, R.; Picci, N. L-lysine pro-prodrug containing trans-ferulic acid for 5-aminosalicylic acid colon delivery: synthesis, characterization and in vitro antioxidant activity evaluation. Chem. Pharm. Bull., 2010, 58(1), 103-105.
98. Dhaneshwar, S. S.; Nagpal D.; Kadam, S. S. Synthesis, kinetic studies and pharmacological screening of colon specific mutual prodrug of 5-aminosalicylic acid with d-glucosamine for inflammatory bowel disease. J. Pharm. Pharmacol., 2006, Sci. Proc., (1), A - 60.
99. Goodman, M. J.; Skinner, J. M.; Truelove, S. C. Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and crohn's disease. Gut, 1977, 18, 219-228.
100. Mahkam, M.; Assadi, M. G.; Zahedifar, R.; Ramesh, M.; Davaran, S. Linear type azo-containing polyurethanes for colon-specific drug delivery. J. Bioactive Compatible Poly, 2004, 19, 45-53.
101. Canevari, M.; Castagliuolo, I.; Brun, P.; Cardin, M.; Schiavon, M.; Pasut, G.; Veronese, F. M. Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery. Int. J. Pharm., 2009, 368, 171-177.
102. Carceller, E.; Salas, J.; Merlos, M.; Giral, M.; Ferrando, R.; Es-camilla, I.; Ramis, J.; Rafanell, J. G.; Forn J. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity. J. Med. Chem., 2001, 44, 3001-3013.
103. Nassif, A.; Longo, W. E.; Mazuski, J. E.; Vernava, A. M.; Kaminski, D. L. Role of cytokines and platelet-activating factor in human inflamed colonic mucosa. Dis. Colon Rectum., 1996, 39, 217-223.
104. Nakamura, J.; Asai, K.; Nishida, K.; Sasaki, H. A novel prodrug of salicylic acid, salicylic acid-glutamic acid conjugate utilizing the hydrolysis in rabbit intestinal microorganisms. Chem. Pharm. Bull, 1992, 40, 2164-2168.
105. Jung, Y; Lee, J. S.; Kim, Y. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J. Pharm. Sci., 2000, 90(11), 1767-1775.
106. Kim, H.; Huh, J.; Jeon, H.; Choi, D.; Han, J.; Kim, Y.; Jung Y. N, N'-Bis (5-aminosalicyl)-l-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis. J. Pharm. Sci., 2009, 98, 159-168.
107. Jung, Y.; Kim, H. H.; Kong, H. S.; Kim Y. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid. Arch. Pharm. Res., 2003, 26(4), 264-269.
108. Vadnerkar, G.; Dhaneshwar, S. S. Design and development of latentiated strategy for delivery of mesalamine to colon, J. Drug Del. Sci. Tech., 2009, 19(5), 321-329.
109. Yomogida, S.; Hua, J.; Sakamoto, K.; Nagaoka, I. Glucosamine suppresses the interleukin-8 production and ICAM-1 expression by TNF-a-stimulated human colonic epithelial cell line HT-29. Int. J. Mol. Med., 2008, 22, 205-211.
110. Yomogida, S.; Kojima, Y.; Tsutsumi-ishii, Y.; Hua, J.; Sakamoto, K.; Nagaoka, I. Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. Int. J. Mol. Med., 2008, 22, 317-323.
111. Dhaneshwar, S. S.; Vadnerkar, G.; Sharma, M.; Ghosh, P. Co-drugs of aminosalicylates and neutraceutical amino sugar for ulcerative colitis. Eur. J. Med. Chem., 2010, (communicated).
112. Pellicciari, R.; Garzon-Aburbeh, A.; Natalini, B.; Marinozzi, M.; Clerici, C; Gentili, G.; Morelli, A. Brush-border-enzyme-mediated intestine-specific drug delivery. amino acid prodrugs of 5-aminosalicylic acid. J. Med. Chem., 1993, 36, 4201-4207.
113. Inoue, M.; Morikawa, M.; Tsuboi, M.; Sugiura, M. Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn. J. Pharmacol, 1979, 29, 9-16.
114. Larsen, C; Harboe, E.; Johansen, M.; Olesen, H. P. Macromolecu-lar prodrugs. XVI. colon targeted delivery-comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm. Res., 1989, 6, 995-999.
115. Jung, Y.; Lee, J. S.; Kim, H. H.; Kim, Y. T.; Kim, Y. M. Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic Acid. Arch. Pharm. Res., 1998, 21, 179-186.
116. Ahmad, S.; Tester, R. F.; Corbett, A.; Karkalas, J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydrate Res., 2006, 341, 2694-2701.
117. Davaran, S.; Hanaee, J.; Khosravi, A. Release of 5-aminosalicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery. J. Control. Release, 1999, 58, 279-287.
118. Babazadeh, M.; Edjlali, L.; Rashidian, L. Application of 2-hydroxyethyl methacrylate polymers in controlled release of 5-aminosalicylic acid as a colon-specific drug. J. Polym. Res., 2007, 14, 207-213.
119. Zoua, M.; Okamoto, H.; Cheng, G.; Hao, X.; Sun, J.; Cui, F.; Danjo, K. Synthesis and properties of polysaccharide prodrugs of 5-aminosalicylic acid as potential colon-specific delivery systems. Eur. J. Pharm. Biopharm., 2005, 59, 155-160.
120. Herzog, R.; Leuschner, J. Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-o-sulfate following local and systemic application. Arzneim. Forsch., 1995, 45, 300-303.
121. Wallace, J. L. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Dig. Liver Dis., 2003, 35(2), S35-S40.
122. Batta, A. K.; Tint, G. S.; Xu, G.; Shefer, S.; Salen, G. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid. J. Lipid Res., 1998, 39, 1641-1646.
123. Wallace, J. L.; Miller, M. J. S. Nitric oxide and mucosal defense: a little goes a long way. Gastroenterol., 2000, 119, 512-520.
124. Elliott, S. N.; McKnight, W.; Cirino, G.; Wallace, J. L. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterol., 1995, 109, 524-530.
125. Wallace, J. L.; Cirino, G.; Caliendo, G.; Sparatore, A.; Santagada, V.; Fiorucci, S. Derivatives of 4 or 5-aminosalicylic acid. US 2006;0270635 A1, 1-36.
126. Distrutti, E.; Sediari, L.; Mencarelli, A.; Renga, B.; Orlandi, S.; Antonelli, E.; Roviezzo, F.; Morelli, A.; Cirino, G.; Wallace, J. L.; Fiorucci, S. Evidence that H2S exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J. Pharm Exp. Ther., 2005, 316, 325-335.
127. Teague, B.; Asiedu, S.; Moore, P. K. The Smooth Muscle Relaxant Effect of Hydrogen Sulphide In Vitro: Evidence for a Physiological Role to Control Intestinal Contractility. Br. J. Pharmacol., 2002, 137, 139-145.
128. O'Brien, C. B.; Senior, J. R.; Arora-Mirchandani, R.; Batta, A. K.; Salen, G. Ursodeoxycholic acid for the treatment of primary scle-rosing cholangitis: a 30-month pilot study. Hepatology, 1991, 14, 838-847.
129. Earnest, D. L.; Holubec, H.; Wali, R. K.; Jolley, C. S.; Bissonnette, M.; Bhattacharyya, A. K.; Roy, H.; Khare, S.; Brasitus, T. A. Che-moprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic Acid. Cancer Res., 1994, 54, 5071-5074.
130. Wali, R. K.; Frawley, B. P.; Hartmann, S.; Roy, H. K.; Khare, S.; Scaglione, S.; Earnest, D. L.; Sitrin, M. D.; Brasitus, T. A.; Bisson-nette, M. Mechanism of action of chemopreventive ursodeoxycho-late in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-a, -bII, and -z. Cancer Res., 1995, 55, 5257-5264.
131. Invernizzi, P.; Salzman, A. L.; Setchell, K. D. R. Ursodeoxycholic acid inhibits induction of the human intestinal epithelial nitric oxide synthase. Hepatology,1995, 22, 361A.
132. Heuman, D. M.; Bajaj, R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gas-troenterol., 1994, 106, 1333-1341.
133. Lover, M. J. Use of 4-ASA as antiinflammatory agent, US 1984, 4,440,763, 1-3.
134. Campieri, M.; Lanfranchi, G. A.; Bertoni, F.; Brignola, C.; Bazzoc-chi, G.; Minguzzi, M. R.; Labò G. A double-blind trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion, 1984, 29, 204-208.
135. Selby, W. S.; Bennett, M. K.; Jewell, D. P. Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion, 1984, 29, 231-234.
136. Gandolfo, J.; Farthing, M.; Powers, G.; Eagen, K.; Goldberg, M.; Berman, P.; Kaplan, M. 4-aminosalicylic acid retention enemas in treatment of distal colitis. Dig. Dis. Sci., 1987, 32, 700-704.
137. Sharma, M. P.; Duphare, H. V.; Dasarathy, S. A. Prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. J. Gas-troenterol. Hepatol., 1992, 7, 173-177.
138. Ginsberg, A. L.; Beck, L. S.; Mc Intosh, T. M.; Nochomovitz, L. E. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double blind, placebo controlled trial. Ann. Int. Med., 1988, 108, 195-199.
139. O'Donnel, L. J.; Arvind, A. S.; Hoang, P.; Cameron, D.; Talbot, I. C.; Jewell, D. P.; Lennard-Jones, J. E.; Farthing, M. J. Double blind controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut, 1992, 33, 947-949.
140. Marteau, P.; Halphen, M. Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-amino-salicylic acid (4-ASA) and 1 gr of 5-amino-salicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis. Gastroenterol. Clin. Biol., 1995, 119, 31-35.
141. Beeken, W.; Howard, D.; Bigelow, J.; Trainer, T.; Roy, M.; Thayer, W.; Wild, G. Controlled trial of 4-ASA in ulcerative colitis. Dig. Dis. Sci., 1997, 42, 354-358.
142. Ginsberg, A. L.; Davis, N. D.; Nochomovitz, L. E. Placebo-controlled trial of ulcerative colitis treatment with oral 4-aminosalicylic acid. Gastroenterol, 1992, 102, 448-452.
143. Schreiber, S.; Howaldt, S.; Raedler, A. Oral 4-Aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. double blind controlled pilot study in the maintenance treatment of crohn's Ileocoli-tis. Gut, 1996, 35, 1081-1085.
144. http://www.fda.gov/ohrms/dockets/dailys/00/mar00/030100/lst009 4.pdf pp. 1-84 [accessed on 08/10/2008].
145. Daniel, F.; Seksik, P.; Cacheux, W.; Jian, R.; Marteau, P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. In-flamm. Bowel Dis., 2004, 10, 258-260.
146. Nielsen, O. H.; Ahnfelt-Rønne, I. 4-aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl. Pharmacol. Toxicol.,1988, 62(4), 223-226.
147. Zhao, Z. B.; Zheng, H. X.; Wei, Y. G.; Liu, J. Synthesis of Azo derivatives of 4-aminosalicylic acid, Chinese Chem. Lett., 2007, 18, 639-642.
148. Huang, W. D.; Chen, C. Q. Synthesis of Polypeptides. Science Press: Beijing, 1985; pp 45-52.
149. Peng, S. Q. Medicinal Chemistry of Polypeptide, Science Press: Beijing, 1993; pp 27-49.
150. Sheng, S. F.; Zheng, H. X.; Liu, J.; Zhao, Z. B. Synthesis of phenol-class azo derivatives of 4-aminosalicylic acid. Chinese Chem. Lett., 2008, 19, 419-422.
151. Zhao, Z. B.; Guo, J.; Wei, Y. G.; Liang, T. D. Synthesis of 4-aminosalicylglycine. Chinese Chem. Lett., 2005, 16(7), 889-892.
152. Dhaneshwar, S. S.; Chail, M.; Patil, M.; Naqvi, S.; Vadnerkar, G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur. J. Med. Chem., 2009, 44, 131-42.
153. Meyers, B. E.; Moonka, D. K.; Davis, R. H. The effect of selected amino acids on gelatin-induced inflammation in adult male mice. Inflammation, 1979, 3, 225-233.
154. Truelove, S. C. Treatment of ulcerative colitis with local hydrocor-tisone. Br. Med. J., 1956, 2, 1267-1272.
155. MacDouglas, I. Treatment of ulcerative colitis with rectal steroids. Lancet, 1963, 1, 826-827.
156. Mulder, C. J. J.; Tytgat, G. N. J. Topical corticosteroids in inflammatory bowel disease. Aliment. Pharmacol. Ther., 1993, 7, 125-130.
157. Crotty, B.; Jewell, D. P. Drug therapy of ulcerative colitis. Br. J. Clin. Pharmacol., 1992, 34, 189-198.
158. Goldsmith, P.; McGarity, B.; Walls, A. F.; Church, M. K.; Mill-ward-Sadler, G. H.; Robertson, D. A. F. Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig. Dis. Sci., 1990, 35(11), 1409-1413.
159. Farmer, R. G.; Schumacher, O. P. Treatment of ulcerative colitis with hydrocortisone enemas: relationship of hydrocortisone absorption, adrenal suppression and clinical response. Dis. Colon Rectum, 1970, 13, 355-361.
160. Cann, P. A.; Holdsworth, C. D. Systemic absorption from hydro-cortisone foam enema in ulcerative colitis. Lancet, 1987, 1(8538), 922-923.
161. Van der Heide, H.; Van denBrandt-Gradel, V.; Tytgat, G. N. J.; Endert, E.; Wiltink, E. H.; Schipper, M. E.; Dekker, W. Comparison of beclomethasone dipropionate and prednisolone-21-phosphate enemas in the treatment of ulcerative proctitis. J. Clin. Gastroenterol., 1988, 10, 169-172.
162. Lennard-Jones, J. E. Betamethasone-17-valserate and prednisolone-21-phosphate retention enema. Br. Med. J., 1971, 3, 84-86.
163. McIntyre, P. B.; Macrea, F. A.; Berghouse, L.; English, J.; Lennard Jones, J. E. Therapeutic benefits from a poorly absorbed predniso-lone enema in distal colitis. Gut, 1985, 26(8), 822-824.
164. Larochelle, P.; Du Souich, P.; Bolte, E.; Lelorier, J.; Goyer, R. Tixocortol pivalate. a corticosteroid with no systemic glucocorti-coid effect after oral, intrarectal and intranasal application. Clin. Pharmacol. Ther., 1983, 3, 343-350.
165. Hanauer, S. B.; Kirsner, J. B.; Barrett, W. E. The treatment of left-sided ulcerative colitis with tixocortol pivalate. Gastroenterol, 1986, 90, 1449A.
166. Bauer, K.; Bamtje, T. A.; Sips, A. P. The effect of inhaled flutica-sone propionate, a new potent corticosteroid in severe asthma. Eur. Resp. J., 1988, 2, 201A.
167. Harding, S. Human Pharmacology of Fluticasone. XIV Congress of the European Academy of Allergology and Clinical Immunology. Berlin, 17-22 September 1989, AS 04.04.
168. Johansson SA. Anderson KE. Brattscand R. Gruvstad E. Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur. J. Clin. Pharmacol., 1982, 22, 523-529.
169. http://www.merck.com/mmpe/sec02/ch018/ch018a.html pg 1-3 accessed on 21/09/09.
170. Wright, E. M.; Bindslev, N. Thermodynamic analysis of Nonelec-trolyte Permeation Across the Toad Urinary Bladder. J. Membr. Biol., 1976, 29, 289-312.
171. Diamond, J. M.; Wright, E. M. Biological membranes: the physical basis of ion and nonelectrolyte selectivity. Annu. Rev. Physiol., 1969, 31, 581-646.
172. Houston, J. B.; Upshall, D. G.; Bridges, J. W. J. A Re-evaluation of the importance of partition coefficients in the gastrointestinal absorption of nutrients. Pharmacol. Exp. Ther., 1974, 189, 244-248.
173. Pownall, H. J.; Hickson, D. L.; Smith, L. C. J. Transport of biological lipophiles: effect of lipophile structure. J. Am. Chem. Soc., 1983, 105, 2440-2445.
174. Tozer, T. N.; Rigod, J.; McLeod, A. D.; Gungon, R.; Hoag, M. K.; Friend, D. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig. Pharm. Res., 1991, 8(4), 445-454.
175. Friend, D. R.; Chang, G. W. Drug glycosides: potential prodrugs for colon-specific drug delivery. J. Med. Chem., 1985, 28, 51-57.
176. Conchie, J, Macdonald, D. C. Glycosidases in the mammalian alimentary tract. Nature, 1959, 184(16), 1233-1235.
177. Haeberlin, B.; Rubas, W.; Nolen, H. W.; Friend, D. R. In vitro evaluation of dexamethasone-beta-d-glucuronide for colon-specific drug delivery. Pharm. Res., 1993, 10, 1553-1562.
178. Cui, N.; Friend, D. R.; Fedorak, R. N. A Budesonide prodrug accelerates treatment of colitis in rats. Gut, 1994, 35, 1439-1446.
179. Jung, Y. J.; Doh, M. J.; Kim, I. H.; Kong, H. S.; Lee, J. S.; Kim, Y. M. Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone. J. Pharm. Pharmacol., 2003, 55, 1075-1082.
180. Kim, I.; Kong, H.; Lee, Y.; Hong, S.; Han, J.; Jung, S.; Jung, Y.; Kim, Y. M. Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine. Pharm. Res., 2009, 26, 415-421.
181. Kong, H.; Lee, Y.; Hong, S.; Han, J.; Choi, B.; Jung, Y.; Kim, Y. M. Sulfate-conjugated methylprednisolone as a colon targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J. Drug Target, 2009, 17, 450-458.
182. Huijghebaert, S.; Sim, S. M.; Back, D. J.; Eyssen, H. J. Distribution of estrone sulfatase activity in the intestine of germ-free and conventional Rats. Steroid Biochem., 1984, 20, 1175- 1179.
183. Kong, H.; Kim, Y.; Lee, Y.; Choi, B.; Jung, S.; Jung, Y.; Kim, Y. M. Sulfate-conjugated methylprednisolone: evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate conjugated prednisolone and dexamethasone. J. Drug. Target, 2009, 17, 159-167.
184. McLeod, A. D.; Fedorak, R. N.; Friend, D. R.; Tozer, T. N.; Cui, N. A Glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterol, 1994, 106(2), 405-413.
185. McLeod, A. D.; Friend, D. R.; Tozer, T. N. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J. Pharm. Sci., 1994, 83, 1284-1288.
186. Varshosaz, J.; Emami, J.; Tavakoli, N.; Fassihi, A.; Minaiyan, M.; Ahmadi, F.; Dorkoosh, F. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int. J. Pharm., 2009, 365(1-2), 69-76.
187. Yano, H.; Hirayama, F.; Arima, H.; Uekama K. Preparation of prednisolone-appended alpha-, beta- and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J. Pharm. Sci., 2001, 90, 493-503.
188. Yano, H.; Hirayama, F.; Kamada, M.; Arima H, Uekama K. Colon-specific delivery of prednisolone appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release, 2002, 79, 103-112.
189. http://ibdcrohns.about.com/od/treatments/a/treatmentibd.htm pg 1-5 accessed on 17/03/2010.
190. Sandborn, W.; Sutherland, L.; Pearson, D.; May, G.; Modigliani, R.; Prantera, C. Azathioprine or 6-mercaptopurine for induction of remission in crohn's disease. Cochrane Database Syst Rev., 2002, 4, CD000545.
191. Nielsen, O. H.; Vainer, B.; Rask-Madsen, J. Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther., 2001, 15(11), 1699-1708.
192. Korelitz, B. I.; Hanauer, S.; Rutgeerts, P.; Present D, Peppercorn M. Post-operative prophylaxis with 6-MP, 5-ASA, or placebo in crohn's disease: A 2-year multicenter trial. Gastroenterol. 1998, 114, A4141.
193. http://health.nytimes.com/health/guides/disease/crohns-disease/medications.html. Pp. 10 [accessed on 17/03/2010].
194. Zacchigna, M.; Cateni, F.; Di Luca, G.; Drioli, S. A simple method for the preparation of PEG-6-mercaptopurine for oral administration References and further reading may be available for this article. To view references and further reading you must purchase this article. Bioorg. Med. Chem. Lett., 2007, 17(23), 6607-6609.
195. Gupta, D.; Mhaske, D. V.; Kadam, S. S.; Dhaneshwar, S. R. Synthesis and evaluation of pharmacological activities of cyclodextrin conjugates of methotrexate. Ind. J. Pharm. Sci., 2003, 66(1), 26-30.
196. Yura, H.; Yoshimura, N.; Hamashima, T.; Akamatsu, K.; Nishi-kawa, M.; Takakura Y.; Hashida, M. Synthesis and pharmacokinet-ics of a novel macromolecular prodrug of tacrolimus (FK506), Fk506-dextran conjugate. J. Control. Release, 1999, 57(1), 87-99.
197. Chung, Y.; Cho, H. Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. Arch. Pharm. Res., 2004, 27(8), 878-883.
198. Lipsky, J. J. Mycophenolate mofetil. Lancet, 1996, 348, 1357-1359.
199. Neurath, M. F.; Wanitschke, R.; Peters, M.; Krummenauer, F.; Meyerzum Buschenfelde, K. H.; Schlaak, J. F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active crohn's disease. Gut, 1999, 44, 625-628.
200. Orth, T.; Peters, M.; Schlaak, J. F.; Krummenauer, F.; Wanitschke, R.; Mayet, W. J.; Galle, P. R.; Neurath, M. F. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcera-tive colitis: a 12-month pilot study. Am. J. Gastroenterol., 2000, 95, 1201-1207.
201. Florin, T. H.; Roberts, R. K.; Watson, M. R.; Radford-Smith, G. L. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust. N. Z. J. Med., 1998, 28, 344-345.
202. Miehsler, W.; Reinisch, W.; Moser, G.; Gangl, A.; Vogelsang, H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active crohn's disease. Am. J. Gas-troenterol., 2001, 96, 782-787.
203. Hupe, D. J.; Azzolina, B. A.; Behrens, N. D. IMP dehydrogenase from the intracellular parasitic protozoan eimeria tenella and its inhibition by mycophenolic acid. J. Biol. Chem., 1986, 261, 8363- 8369.
204. 0,+. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293, G1046-G1053.
205. Zeeh, J. M.; Riley, N. E; Hoffmann, P.; Ruwe, M.; Goebell, H.; Gerken, G.; Dignass, A. U. Mycophenolate mofetil reduces tissue damage and inflammation in an experimental model of colitis in rats. Scand. J. Gastroenterol., 2001, 36, 66-70.
206. Shanahan F. Crohn's Disease. Lancet. 2002, 359, 62-69.
207. Shanahan F. The Host-microbe Interface within the Gut. Best Pract Res. Clin. Gastroenterol., 2002, 16, 915-931.
208. Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm. Bowel Dis., 2004, 10, S16-S24.
209. Brandt, W.; Bemstein, L. H.; Boley, S. J.; Frank, M. S. Metronida-zole therapy for perineal crohn's disease: a follow-up study. Gas-troenterol., 1982, 83, 383-387.
210. Turunen, U.; Fxkkila, V.; Valtonen, V.; Seppala, X. Long-term outcome of ciprofloxacin treatment in severe perianal or tistulous crohn's disease. Gastroenterol., 1993, 104, 793A.
211. Mitchell, J.; Spirt, M. D. Antibiotics in inflammatory bowel disease: new choices for an old disease. Am. J. Gastroenterol., 2008, 89(7), 974-978.
212. Gionchetti, P.; Rizzello, F.; Lammers, K. M.; Morselli, C.; Tam-basco, R.; Campier, M. Antimicrobials in the management of inflammatory bowel disease. Digestion, 2006, 73(1), 77-85.
213. Lee, J. S.; Jung, Y. J.; Doh, M. J.; Kim, Y. M. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev. Ind. Pharm., 2001, 27, 331-336.
214. Namazi, H.; Kanani, A. Synthesis of new prodrugs based on (3-cd as the natural compounds containing p-lactam antibiotics. J. Bioact. Comp. Poly, 2007, 22(1), 77-88.
215. Grisham, M. B.; Granger, D. N. Neutrophil-mediated mucosal injury. role of reactive oxygen metabolites. Dig. Dis. Sci., 1988, 33, 6S-15S.
216. Beckman, K. B.; Ames, B. N. Oxidative decay of DNA. J. Biol. Chem., 1997, 272, 19633-19636.
217. Babbs, C. F. Oxygen radicals in ulcerative colitis. Free Radic. Biol. Med., 1992, 13, 169-181.
218. Oz, H. S.; Chen, T.; McClain, C. J.; deVilliers, W. Antioxidants a novel therapy in a murine model of colitis. J. Nutri. Biochem., 2005, 16, 297-304.
219. Oz, H. S.; Chen, T.; de Villiers, W.; McClain, C. Metallothionein overexpression does not protect against inflammatory bowel disease in a DSS murine colitis model. Med. Sci. Monit., 2005, 11, 69-73.
220. Koch, T. R.; Yuan, L. X.; Fink, J. G.; Petro, A.; Opara, E. C. Induction of enlarged intestinal lymphoid aggregates during acute glutathione depletion in a murine model. Dig. Dis. Sci., 2000, 45, 2115-2121.
221. Tian, J.; Washizawa, N.; Gu, L. H.; Levin, M. S.; Wang, L.; Rubin, D. C; Mwangi, S.; Srinivasan, S.; Gao, Y.; Jones, D. P.; Ziegler, T. R. Stimulation of colonic mucosal growth associated with oxidized redox status in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol, 2007, 292, R1081-R1091.
222. Roberts, J. C; Nagasawa, H. T.; Zera, R. T.; Fricke, R. F.; Goon, D. J. Prodrugs of L-cysteine as protective agents against aceta-minophen-induced hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(Polyacetoxyalkyl)-thiazolidine-4(R)-carboxylic acids. J. Med. Chem., 1987, 30, 1891-1896.
223. Nagasawa, H. T.; Goon, D. J.; Muldoon, W. P. Zera, R. T. 2-Substituted thiazolidine-4(R)-carboxylic acids as prodrugs of l-cysteine, protection of mice against acetaminophen hepatotoxicity. J. Med. Chem., 1984, 27, 591-596.
224. Berkeley, L. I.; Cohen, J. F.; Crankshaw, D. L.; Shirota, F.; Nagasawa, H. T. Hepatoprotection by l-cysteine-glutathione mixed disulfide, a sulfhydryl-modified prodrug of glutathione. J. Biochem. Mol. Toxicol, 2003, 17, 95-97.
225. Eriksson, S. A.; Mannervik, B. The Reduction of the l-cysteine-glutathione mixed disulfide in rat liver. involvement of an enzyme catalyzing thiol-disulfide interchange. FEBS Lett., 1970, 7, 26-28.
226. Oz, H.S.; Chen, T.; Nagasawa, H. Comparative efficacies of two cysteine prodrugs and a glutathione delivery agent in a colitis model. Translat. Res., 2007, 150, 122-129.
227. Srinivasan, C; Williams, W. M.; Ray, M. B.; Chen, T. S. Prevention of acetaminophen-induced liver toxicity by 2(r,s)-n-propylthiazolidine-4(r)-carboxylic acid in mice. Biochem. Pharmacol, 2001, 61, 245-252.
228. Rodrigues, C. M.; Kren, B. T.; Steer, C. J.; Setchell, K. D. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterol, 1995, 109, 1835-1844.
229. Nolen, H. W.; Friend, D. R. Menthol p-d-glucuronide: a potential prodrug for the treatment of irritable bowel syndrome. Pharm. Res., 1994, 11(12), 1707-1711.
230. Petri, W. A. Therapy of intestinal protozoa. Trends Parasitol, 2003, 19, 523-526.
231. Stanley S. L. Amoebiasis. Lancet, 2003, 361, 1025-1034.
232. Freeman, C. D.; Klutman, N. E.; Lamp, K. C. Metronidazole. A therapeutic review and update. Drugs, 1997, 54, 679-708.
233. Ludlum, D. B.; Colinas, R. J.; Kirk, M. C. Mehta, J. R. Reaction of reduced metronidazole with guanosine to form an unstable adduct. Carcinogenesis, 1988, 9, 593-596.
234. Leitsch, D.; Kolarich, D.; Wilson, I. B.; Altmann, F.; Duchene, M. Nitroimidazole action in entamoeba histolytica: a central role for thioredoxin reductase. PLoS. Biol, 2007, 5(8), e211.
235. Lau, A. H.; Lam, N. P.; Piscitelli, S. C; Wilkes, L.; Danziger, L. H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet, 1992, 23, 328-364.
236. Lamp, K. C; Freeman, C. D.; Klutman, N. E.; Lacy, M. K. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet, 1999, 36, 353-373.
237. Kapoor, K.; Chandra, M.; Nag, D.; Paliwal, J. K.; Gupta, R. C.; Saxena, R. C. Evaluation of metronidazole toxicity: A prospective study. Int. J. Clin. Pharmacol. Res., 1999, 19, 83-88.
238. Kim D, Hong S, Jung S, Jung, Y. J.; Kim, Y. M. Synthesis and evaluation of N-nicotinoyl-2-{2-(2-methyl-5-nitroimidazol-1-yl)ethyloxy}-D,L-glycine as a colon-specific prodrug of metroni-dazole. J. Pharm. Sci., 2009, 98(11), 4161-4169.
239. Crohn, B. B.; Rosenberg, H. The sigmoidoscopic picture of chronic ulcerative colitis. Am. J. Med. Sci., 1925, 170, 220-228.
240. Stewart, B. W.; Kleihus, P. Eds.; World Cancer Report. IARC Press: Lyon, 2003; pp 1-352.
241. Diasio, R. B.; Harris, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 1989, 16, 215-37.
242. Mukherjee, K. L.; Heidelberger, C. Studies on fluorinated pyrimidines IX. the degradation of 5-fluorouracil-6-C14. J. Biol. Chem., 1960, 235, 433-437.
243. Ho, D. H.; Townsend, L.; Luna, M. A. Bodey, G. P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res., 1986, 6, 781-784.
244. Lee, J. S.; Jung, Y. J.; Kim, Y. M. Synthesis and evaluation of n-acyl-2-(5-fluorouracil-1-yl)-d,l-glycine as a colon-specific prodrug of 5-fluorouracil. J. Pharm. Sci., 2001, 90, 1787-1794.
245. Lee, J.; Rho, J.; Yang, Y.; Kong, H.; Jung Y. J.; Kim, Y. Synthesis and in vitro evaluation of n-nicotinoylglycyl-2-(5-fluorouracil-1-yl)-d, l-glycine as a colon-specific prodrug of 5-fluorouracil. J. Drug Target, 2007, 15, 199-205.
246. Prasad, K. N. Butyric acid: A small fatty acid with diverse biological functions. Life Sci., 1980, 27, 1351-1358.
247. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem., 1982, 42, 65-82.
248. Toscani, A.; Soprano, D. R.; Soprano, K. J. Molecular analysis of sodium butyrate-induced growth arrest. Oncogen. Res., 1988, 3, 223-238.
249. Medina, V.; Edmonds, B.; Young, G. P.; James, R.; Appleton, S.; Zalewski, P. D. Induction of caspase-3 protease activity and apop-tosis by butyrate and thichostatin a (inhibitors of histone deacety-lase): dependence on cytochrome c-dependent pathway. Cancer Res., 1997, 37, 3697-3707.
250. Cummings, J. H. Short chain fatty acids in the human colon. Gut, 1981, 22, 763-779.
251. Rephaeli, A.; Zhuk, R.; Nudelman, A. Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action and clinical applications. Drug Dev. Res., 2000, 50, 379-391.
252. Gao, S. Q.; Lu, Z. R.; Petri, B.; Kopečková, P.; Kopeček, J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1, 6-elimination spacer. J. Control. Rel., 2006, 110, 323-331.
253. Pillay, V.; Fassihi, R. Unconventional dissolution methodologies. J. Pharm. Sci., 1999, 88, 843-851.
254. Jain, S. K.; Chourasia, M. K.; Dengre, R. Azo polymers for colon targeted drug delivery. Ind. J. Pharm. Sci., 2005, 67(1), 43-50.
255. Takeuchi, H.; Yasuji, T.; Yamamoto, H.; Kawashima, Y. Spray-dried lactose composite particles containing an ion complex of alginate-chitosan for designing a dry-coated tablet having a time-controlled releasing function. Pharm. Res., 2000, 17, 94-99.
256. Wong, D.; Larrabee, S.; Clifford, K.; Tremblay, J.; Friend, D. R. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J. Control. Release, 1997, 47, 173-179.
257. Molly, K.; Vande Woestyne, M.; Verstraete, W. Development of a five-step multichamber reactor as a simulation of the human intestinal microbial ecosystem. Appl. Microbiol. Biotechnol., 1993, 39, 254-258.
258. Van den Mooter, G.; Samyn, C; Kinget, R. In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with Azo polymers in rats. Pharm. Res., 1995, 12, 244-247.
259. Gardner, N.; Haresign, W.; Spiller, R.; Faraj, N.; Wiseman, J.; Norbury, H.; Illum, L. Development and validation of a pig model for colon-specific drug delivery. J. Pharm. Pharmacol, 1996, 48, 689-693.
260. Saffran, M.; Field, J. B.; Pena, J.; Jones, R. H.; Okuda, Y.; Oral insulin in diabetic dogs. J. Endocrinol, 1991, 131, 267-278.
261. Karali, T. T. Comparison of the gastrointestinal anatomy, physiology and biochemistry of human and commonly used laboratory animals. Biopharm. Drug Dispos., 1995, 16, 351-380.
262. Neurath, M. F. Animal models of inflammatory bowel diseases. Ernst. Schering Res. Found Workshop, 2005, 50, 119-132.
263. Wirtz, S.; Neurath, M. F. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal. Dis., 2000, 15, 144-160.
264. Neurath, M. F.; Fuss, I.; Kelsall, B. L.; Stuber, E.; Strober, W. Antibodies to IL-12 abrogate established experimental colitis in Mice. J. Exp. Med., 1995, 182, 1280-1289.
265. Boirivant, M.; Fuss, I. J.; Chu, A.; Strober, W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin-4. J. Exp. Med., 1998, 188, 1929-1939.
266. Kuhn, R.; Lohler, J.; Rennick, D.; Rajewsky, K.; Mueller, W. Inter-leukin-10 deficient mice develop chronic enterocolitis. Cell, 1993, 75, 263-274.
267. Mizoguchi, A.; Mizoguchi, E.; Smith, R. N.; Preffer, F. I. Bhan, A. K. The suppressive role of B cells in chronic colitis of T cell receptor a mutant mice. J. Exp. Med., 1997, 186, 1749-1756.
268. Mizoguchi, A.; Mizoguchi, E.; Bhan, A. K. The critical role for interleukin-4 but not interferon-y in the pathogenesis of colitis in t-cell receptor a mutant mice. Gastroenterol, 1999, 116, 320-326.
269. Hartmann, G.; Bidlingamaier, C; Seigmund, B.; Albrich, S.; Schulze, J.; Tschoep, K.; Eigler, A.; Lehr, H. A.; Endres, S. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther., 2000, 292, 22-30.
270. Axelsson, L. G.; Landstrom, E.; Bylund-fellenius, A. C. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment. Pharmacol. Ther., 1998, 12, 925-934.
271. Zingarelli B.; Salvatore C; Csaba, S.; Salzman, A. Mercap-toetrhylguanidine, A combined inhibitor of nitric oxide synthase and peroxynitrite scavanger, reduces trinitrobenzenesulphoinic acid induced colonic damage in rats. J. Pharmacol. Exp. Ther., 1998, 287, 1048-1055.
272. Neurath, M. F.; Becker, C; Barbulescu, K. Role of NF-kB in immune and inflammatory responses in the gut. Gut, 1998, 43, 856-886.
273. Ljung, T.; Lundberg, S.; Varsanyi, M.; Johansson, C; Schmidt, P. T.; Herulf, M.; Lundberg, J. O.; Hellström, P. M. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders, World J. Gastroenterol, 2006, 12(21), 3386-3392.
274. Krawisz, J. E.; Sharon, P.; Stenson, W. F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterol, 1984, 87, 1344-1350.
275. Nugent, S. G.; Kumar, D.; Rampton, D. S.; Evans, D. F. Intestinal luminal ph in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut, 2001, 48, 571-577.
276. Guarner, F.; Malagelada, J. R. Gut flora in health and disease. Lancet, 2003, 361, 512-519.